¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Solicitud de permisos - Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2016

© Thomson Reuters, Journal Citation Reports, 2016

Indexada en:

Index Current Contents/Clinical Medicine, JCR, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, CANCERLIT, SCOPUS


  • Factor de Impacto: 1,714 (2016)
  • SCImago Journal Rank (SJR):0,43
  • Source Normalized Impact per Paper (SNIP):0,653

© Thomson Reuters, Journal Citation Reports, 2016

- DOI: 10.1016/j.eimc.2017.10.012
Scientific letter
Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection
Sofosbuvir más daclatasvir como alternativa en pacientes con infección por el virus de la hepatitis C genotipo 2 en hemodiálisis
Jara Llenas-Garcíaa,b,, , Sergio Padillaa,c, Mar Masiáa,c, Félix Gutiérreza,c
a Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de l’Almazara, Elche, Alicante, Spain
b Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain
c Universidad Miguel Hernández, Alicante, Spain
Dear Editor,

Treatment of hemodialyzed patients with HCV infection is challenging and data on safety and effectiveness of the new direct-acting antivirals (DAAs) are scarce and concentrated in genotypes 1 and 4.1,2 For patients with genotype-2-HCV (gen2-HCV) infection and estimated glomerular filtration rate (eGFR)<30mL/min, current guidelines recommend pegylated interferon-α (PEG-IFN) and dose-adjusted ribavirin when treatment has been elected before kidney transplantation.2 Preferred regimens for gen2-HCV-infection without renal impairment are sofosbuvir/velpatasvir (SOF/VEL), daclatasvir (DCV)+sofosbuvir (SOF) and SOF+ribavirin.3,4 Although SOF is restricted to patients with eGFR ≥30mL/min, real world data in patients with lower eGFR show a good effectiveness rate with increased side effects.5 SOF toxicity may be driven by accumulation of GS-331007, a metabolite eliminated renally and partially extracted by hemodialysis. Recently, growing evidence of the safety and effectiveness of SOF in hemodialyzed patients has arisen1,6 with 100% sustained viral response at 12 weeks (SVR12).

We hereby describe the case of a 50-year-old Moroccan immigrant with chronic kidney disease stage 5 on hemodialysis. On September 2015, he had an acute gen2-HCV-infection. Twelve months later, his HCV viral load was 2,708,805IU/mL and elastography was 9.1kPa. IL28B genotype was CT. A 12-weeks course of daily SOF400mg plus DCV60mg was started. On hemodialysis days, patient was instructed to take SOF and DCV after the hemodialysis session. SOF/VEL was not available at that time. During HCV treatment he continued taking his chronic medications that included gemfibrozil, omeprazole, nifedipine, calcifediol, sevelamer, cinacalcet, folic acid, calcium acetate/magnesium carbonate and sodium bicarbonate; carvedilol was replaced by doxazosin to avoid bradycardia. The patient was closely monitored with weekly clinical visits, weekly blood cell count, biochemistry (including liver function tests) and electrocardiogram. Therapeutic drug monitoring was not available. He had no side effects besides a grade 2 self-limited episode of vomits 3 days after starting medication. He successfully achieved SVR12.

Best option for gen2-HCV patients in hemodialysis is unknown and DAAs’ data come from case reports or small case series. Desnoyer et al. included only one gen2-HCV patient successfully treated with SOF+ribavirin6; other studies report no gen2-HCV cases or no extractable data.5 In our opinion, until more treatment options become available, SOF+DCV could be a good option if treatment is elected before kidney transplantation. This combination may be better tolerated and more effective than PEG-IFN+ribavirin. It is mandatory to monitor them very closely for hepatobiliary and cardiovascular side effects.

Financial support


F. Fabrizi,P. Martin,P. Messa
New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant
Kidney Int, 89 (2016), pp. 988-994 http://dx.doi.org/10.1016/j.kint.2016.01.011
AASLD-IDSA. Unique patient populations: patients with renal impairment. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-renal-impairment [cited 17.12.16].
O. Falade-Nwulia,C. Suarez-Cuervo,D.R. Nelson,M.W. Fried,J.B. Segal,M.S. Sulkowski
Oral direct-acting agent therapy for hepatitis C virus infection
Ann Intern Med, 166 (2017), pp. 637-648 http://dx.doi.org/10.7326/M16-2575
Guías AEEH/SEIMC de manejo de la Hepatitis C
(2017)pp. 1-80
Available from: http://aeeh.es/wp-content/uploads/2017/06/consenso.pdf [cited 26.07.17]
V. Saxena,F.M. Koraishy,M.E. Sise,J.K. Lim,M. Schmidt,R.T. Chung
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function
Liver Int, 36 (2016), pp. 807-816 http://dx.doi.org/10.1111/liv.13102
A. Desnoyer,D. Pospai,M.P. Lê,A. Gervais,A. Heurgué-Berlot,A. Laradi
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C
Corresponding author. (Jara Llenas-García jarallenas@gmail.com)
Copyright © 2017. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica